✦ LIBER ✦

3500 ORAL Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma

✍ Scribed by G.K. Abou Alfa; P. Johnson; J. Knox; J. Lacava; T. Leung; A. Mori; M.A. Leberre; D. Voliotis; L. Saltz

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multi-centre randomized phase II study

✍ Tony S. K. Mok; Thomas W. T. Leung; Shou-Dong Lee; Yee Chao; Anthony T. C. Chan; 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 79 KB

Prospective, randomized, double-blind, m

✍ K Hoffmann; H Glimm; B Radeleff; G Richter; C Heining; I Schenkel; A Zahlten-Hin 📂 Article 📅 2008 🏛 BioMed Central 🌐 English ⚖ 260 KB

Rationale and Design of MARQUEE: A Phase

✍ Giorgio V. Scagliotti; Silvia Novello; Joan H. Schiller; Vera Hirsh; Lecia V. Se 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 332 KB

Doxorubicin plus ifosfamide with rhGM-CS

✍ W. P. Steward; J. Verweij; R. Somers; G. Blackledge; M. Clavel; A. T. Van Ooster 📂 Article 📅 1991 🏛 Springer-Verlag 🌐 English ⚖ 561 KB